focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Just been re-reading previous RNSs and the latest Issue of Equity makes reference to EMI Share Options (Enterprise Management Incentives) whereas the previous one (11/02/20) makes reference to a SIP (Share Incentive Plan). From some research it appears the EMI scheme is far more tax efficient but company can only qualify if the gross assets do not exceed £30M. Was the scheme changed at some point and would the near realisation of potential IP valuation (Affimers) nod towards a not too subtle change here that would later disqualify further EMI shares as an option? Don’t know if I’m reading too much into it as not well versed in this area but hopefully someone out there is....
https://www.labiotech.eu/interviews/ablynx-refresh-brussels-may18/
https://ukinvestormagazine.co.uk/avacta-shares-surge-on-covid-19-treatment-progress/
“I look forward to updating the market further on this and on the development of a COVID-19 antigen rapid saliva test with Cytiva which continues apace."
All good on the POC test front then and date I suggest perhaps ahead of schedule?
RD - do you have a crystal ball!! Seems you were spot on. Looks like you also got your answer over the required funding for this type of treatment - partnership with someone who has those means. Great research and much appreciated. GLA
https://avacta.com/avacta-ceo-alastair-smith-interviewed-on-sky-news/
There was a question the other day about recruitment and numbers....this may be of interest...
https://twitter.com/saralayad/status/1257656925149376512?s=21
Read the specifications - it is a nasal swab ...
*Testing is authorized to be performed at moderate complexity/high complexity laboratories, or at the Point of Care (POC) in patient care settings operating under a CLIA Certificate of Waiver
https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/howobtaincertificateofwaiver.pdf
I would say this isn’t in the same ball park as the Avacta rapid test, but that’s my opinion....
https://www.google.ae/amp/s/www.***************************/avacta-group-ships-sars-cov-2-affimer-reagents-to-cytiva-and-adeptrix/412820223%3famp
RNS Number : 3688M
4d Pharma PLC
11 May 2020
4D pharma plc
(the "Company" or "4D")
Successful completion of immuno-oncology study safety phase
Leeds, UK, 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces successful completion of Part A of a Phase I/II clinical trial of MRx0518 in combination with immune checkpoint inhibitor Keytruda® (pembrolizumab). Part A of the study evaluated the therapeutic combination in patients with advanced solid tumors who had previously shown an initial clinical benefit to PD-1/PD-L1 immune checkpoint inhibitors, but had subsequently developed secondary resistance and progressive disease.
The safety review committee for the study has evaluated data collected during the Dose Limiting Toxicity (DLT) period of the trial, the first cycle of treatment for the first 12 patients. The committee determined that it is safe to proceed to Part B of the study. Part B of the study has now commenced and will assess clinical benefit and safety, enrolling up to an additional 30 patients per tumor type cohort (up to a total of 120). Enrolment will be expanded to additional trial locations and sites. The study is open label and an update on progress is anticipated later in the year.
Dr. Alex Stevenson, Chief Scientific Officer, 4D pharma, commented:
"As with all of 4D pharma's Live Biotherapeutics targeting a range of conditions, a good safety profile for MRx0518 was expected. It is important that this has been confirmed in Part A of this study in combination with a PD-1 immune checkpoint inhibitor.
"Commencing Part B of the study and expanding enrolment will enable us to build on the very encouraging preliminary signals of efficacy we have seen. These initial results indicate the potential for MRx0518 to be a game-changing immunotherapy for this particularly difficult-to-treat patient population for which all other therapeutic options have been exhausted."
Dr. Jean-Pierre Bizzari, chair of the New Drug Advisory committee of the EORTC1, and formerly Executive Vice-President and Head of Clinical Oncology Development at Celgene, commented:
"The data from Part A of the study are very encouraging and quite promising, with the drug combination exhibiting an excellent safety profile and early signs of clinical benefit in heavily pre-treated patients with advanced metastatic disease. Further studies are warranted and I look forward to working with 4D in evaluating this treatment in a larger population of patients in Part B of the study".
4D pharma previously reported positive interim clinical observations from Part A, in which three of the first six patients enrolled achieved a clinical benefit (complete response, partial response, or stable disease for six months or more), evidence of increased tumor-infiltrating lymphocytes (TILs) following treatment, and no drug related serious adverse events. These patients continue to show